Centers for Disease Control and Prevention, 1252-1253 [05-288]
Download as PDF
<![CDATA[
1252
Federal Register / Vol. 70, No. 4 / Thursday, January 6, 2005 / Notices
Environmental protection, Pesticides
and pest.
Dated: December 23, 2004.
Jack E. Housenger,
Acting Director, Antimicrobials Division,
Office of Pesticide Programs.
[FR Doc. 05–260 Filed 1–5–05; 8:45 am]
BILLING CODE 6560–50–S
Internal personnel rules and procedures
or matters affecting a particular
employee.
FOR FURTHER INFORMATION CONTACT: Mr.
Robert Biersack, Press Officer,
Telephone: (202) 694–1220.
The Director, Management Analysis and
Services Office has been delegated the
authority to sign Federal Register notices
pertaining to announcements of meetings and
other committee management activities for
both CDC and the Agency for Toxic
Substances and Disease Registry.
Darlene Harris,
Deputy Secretary of the Commission.
[FR Doc. 05–377 Filed 1–4–05; 2:33 pm]
List of Subjects
Dated: December 30, 2004.
B. Kathy Skipper,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 05–271 Filed 1–5–05; 8:45 am]
BILLING CODE 6715–01–M
FEDERAL COMMUNICATIONS
COMMISSION
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[Report No. 2684]
Petitions for Reconsideration and
Clarification of Action in Rulemaking
Proceeding
December 1, 2004.
Petitions for Reconsideration and
Clarification have been filed in the
Commission’s Rulemaking proceeding
listed in this Public Notice and
published pursuant to 47 CFR Section
1.429(e). The full text of this document
is available for viewing and copying in
Room CY–B402, 445 12th Street, SW.,
Washington, DC or may be purchased
from the Commission’s copy contractor,
Best Copy and Printing, Inc. (BCPI) (1–
800–378–3160). Oppositions to these
petitions must be filed by January 21,
2005. See Section 1.4(b)(1) of the
Commission’s rules (47 CFR 1.4(b)(1)).
Replies to an opposition must be filed
within 10 days after the time for filing
oppositions have expired.
Subject: In the Matter of Second
Periodic Review of the Commission’s
Rules and Policies Affecting the
Conversion to Digital Television (MB
Docket No. 03–15).
Number of Petitions Filed: 11.
Marlene H. Dortch,
Secretary.
[FR Doc. 05–259 Filed 1–5–05; 8:45 am]
BILLING CODE 6712–01–M
FEDERAL ELECTION COMMISSION
Sunshine Act Notices
Tuesday, January 11,
2005 at 10 a.m.
PLACE: 999 E Street, NW., Washington,
DC.
STATUS: This meeting will be closed to
the public.
Compliance matters pursuant to 2
U.S.C. § 437g.
Audits conducted pursuant to 2 U.S.C.
§ 437g, § 438(b), and Title 26, U.S.C.
Matters concerning participation in civil
actions or proceedings or arbitration.
DATE AND TIME:
VerDate jul<14>2003
15:45 Jan 05, 2005
Jkt 205001
BILLING CODE 4163–18–P
Centers for Disease Control and
Prevention
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Advisory Committee on Childhood
Lead Poisoning Prevention (ACCLPP):
Meeting
Centers for Disease Control and
Prevention
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the National Center for
Environmental Health (NCEH) of the
Centers for Disease Control and
Prevention (CDC) announces the
following committee meeting.
Name: Advisory Committee on Childhood
Lead Poisoning Prevention.
Times and Dates: 8:30 a.m.–5 p.m., March
22, 2005; 8:30 a.m.–12:30 p.m., March 23,
2005.
Place: Sheraton New Orleans Hotel, 500
Canal Street, New Orleans, LA 70130,
Telephone: (504) 595–6211 or toll free 1–
888–627–7033.
Status: Open to the public, limited only by
the space available. The meeting room
accommodates approximately 75 people.
Purpose: The Committee provides advice
and guidance to the Secretary; the Assistant
Secretary for Health; and the Director, CDC,
regarding new scientific knowledge and
technological developments and their
practical implications for childhood lead
poisoning prevention efforts. The committee
also reviews and reports regularly on
childhood lead poisoning prevention
practices and recommends improvements in
national childhood lead poisoning
prevention efforts.
Matters To Be Discussed: Update on the
Lead and Pregnancy Workgroup Agenda
activities, ACCLPP process for work group
projects, updates of the clinical and public
health implications of adverse health effects
of blood lead levels less than 10 µg/dL.
Agenda items are subject to change as
priorities dictate.
Opportunities will be provided during the
meeting for oral comments. Depending on the
time available and the number of requests, it
may be necessary to limit the time of each
presenter.
For Further Information Contact: Crystal
M. Gresham, Program Analyst, Lead
Poisoning Prevention Branch, Division of
Emergency and Environmental Health
Services, NCEH, CDC, 4770 Buford Hwy, NE.,
M/S F–40, Atlanta, Georgia 30341, telephone
(770) 488–7490, fax (770) 488–3635.
PO 00000
Frm 00033
Fmt 4703
Sfmt 4703
Publication of closed meeting
summary of the Advisory Board on
Radiation and Worker Health (ABRWH),
National Institute for Occupational
Safety and Health (NIOSH).
ACTION:
Committee Purpose: This board is
charged with (a) providing advice to the
Secretary, HHS on the development of
guidelines under Executive Order
13179; (b) providing advice to the
Secretary, HHS on the scientific validity
and quality of dose reconstruction
efforts performed for this Program; and
(c) upon request by the Secretary, HHS,
advise the Secretary on whether there is
a class of employees at any Department
of Energy facility who were exposed to
radiation but for whom it is not feasible
to estimate their radiation dose, and on
whether there is reasonable likelihood
that such radiation doses may have
endangered the health of members of
this class.
Background: The Advisory Board on
Radiation and Worker Health met on
December 13, 2004, in closed session to
discuss Individual Case Dose
Reconstruction Reviews. The discussion
involved individual dose reconstruction
case reviews. The individual cases the
ABRWH discussed included personal
information of a confidential nature
where disclosure would constitute a
clearly unwarranted invasion of
personal privacy and, therefore, could
not be disclosed. A Determination to
Close the meeting was approved and
published, as required by the Federal
Advisory Committee Act.
Summary of the Meeting: Attendance
was as follows:
Board Members:
Paul L. Ziemer, Ph.D., Chair.
Lew Wade, Ph.D., Executive Secretary
(Pro Tem).
Antonio Andrade, Ph.D., Member.
Roy L. DeHart, M.D., M.P.H., Member.
E:\FR\FM\06JAN1.SGM
06JAN1
Federal Register / Vol. 70, No. 4 / Thursday, January 6, 2005 / Notices
Richard L. Espinosa, Member.
Michael H. Gibson, Member.
Mark A. Griffon, Member.
James M. Melius, M.D., Dr.P.H.,
Member.
Wanda I. Munn, Member.
Charles L. Owens, Member.
Robert W. Presley, Member.
Genevieve S. Roessler, Ph.D.,
Member.
NIOSH Staff:
Fred Blosser, Cori Homer, Stu
Hinnefeld, Liz Homoki-Titus, Ted
Katz, Rob McGolerick, Jim Neton,
and Diane Porter.
DOL Staff:
Shelby Hallmark, Jeff Kotsch, Jeff
Nesvet, and Pete Turcic.
GAO Staff:
Mary Nugent.
SC&A Staff:
Hans Behling, Joe Fitzgerald, John
Mauro.
Ray S. Green, Court Recorder.
Dr. Ziemer called to order the
Advisory Board on Radiation and
Worker Health (ABRWH) in closed
session on December 13, 2004 at 1:30
p.m. The purpose of the closed meeting
was to discuss the Individual Case Dose
Reconstruction Reviews. This action
will allow the ABRWH to fulfill its
statutory duty to advise the Secretary of
Health and Human Services on the
scientific validity and quality of dose
estimation and reconstruction efforts
being performed for purposes of the
compensation program under EEOICPA.
General topics discussed:
• Closed session procedures.
• Case reviews presented.
• Prepared motion for consideration
by the full Board regarding how to
proceed with the 20 cases; the motion
was approved by unanimous vote, then
shared and discussed in open session by
the Board on the following day. Dr. Paul
Ziemer adjourned the closed session of
the ABRWH meeting at 4:50 p.m. with
no further business being conducted by
the ABRWH.
Contact Person for More Information:
Larry Elliott, Executive Secretary,
ABRWH, NIOSH, CDC, 4676 Columbia
Parkway, Cincinnati, Ohio 45226,
telephone 513/533–6825, fax 513/533–
6826.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities for both CDC and
the Agency for Toxic Substances and
Disease Registry.
15:45 Jan 05, 2005
BILLING CODE 4163–19–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. 2004N–0558]
Agency Information Collection
Activities; Proposed Collection;
Comment Request; Evaluating the
Safety of Antimicrobial New Animal
Drugs With Regard to Their
Microbiological Effects on Bacteria of
Human Health Concern
AGENCY:
Jkt 205001
Food and Drug Administration,
HHS.
ACTION:
Summary/Minutes
VerDate jul<14>2003
Dated: December 30, 2004.
B. Kathy Skipper,
Acting Director, Management Analysis and
Services Office, Centers for Disease Control
and Prevention.
[FR Doc. 05–288 Filed 1–5–05; 8:45 am]
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is announcing an
opportunity for public comment on the
proposed collection of certain
information by the agency. Under the
Paperwork Reduction Act of 1995 (the
PRA), Federal agencies are required to
publish notice in the Federal Register
concerning each proposed collection of
information, including each proposed
extension of an existing collection of
information, and to allow 60 days for
public comment in response to the
notice. This notice solicits comments on
the reporting requirements for assessing
the antimicrobial resistance concerns as
part of the overall preapproval safety
evaluation of new animal drugs,
focusing on the effect of antimicrobial
new animal drugs on bacteria of human
health concern.
DATES: Submit written or electronic
comments on the collection of
information by March 7, 2005.
ADDRESSES: Submit electronic
comments on the collection of
information to https://www.fda.gov/
dockets/ecomments. Submit written
comments on the collection of
information to the Division of Dockets
Management (HFA–305), Food and Drug
Administration, 5630 Fishers Lane, rm.
1061, Rockville, MD 20852. All
comments should be identified with the
docket number found in brackets in the
heading of this document.
FOR FURTHER INFORMATION CONTACT:
Denver Presley, Office of Management
Programs (HFA–250), Food and Drug
Administration, 5600 Fishers Lane,
Rockville, MD 20857, 301–827–1472.
PO 00000
Frm 00034
Fmt 4703
Sfmt 4703
1253
Under the
PRA (44 U.S.C. 3501–3520), Federal
agencies must obtain approval from the
Office of Management and Budget
(OMB) for each collection of
information they conduct or sponsor.
‘‘Collection of information’’ is defined
in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes agency requests
or requirements that members of the
public submit reports, keep records, or
provide information to a third party.
Section 3506(c)(2)(A) of the PRA (44
U.S.C. 3506(c)(2)(A)) requires Federal
agencies to provide a 60-day notice in
the Federal Register concerning each
proposed collection of information,
including each proposed extension of an
existing collection of information,
before submitting the collection to OMB
for approval. To comply with this
requirement, FDA is publishing notice
of the proposed collection of
information set forth in this document.
With respect to the following
collection of information, FDA invites
comments on these topics: (1) Whether
the proposed collection of information
is necessary for the proper performance
of FDA’s functions, including whether
the information will have practical
utility; (2) the accuracy of FDA’s
estimate of the burden of the proposed
collection of information, including the
validity of the methodology and
assumptions used; (3) ways to enhance
the quality, utility, and clarity of the
information to be collected; and (4)
ways to minimize the burden of the
collection of information on
respondents, including through the use
of automated collection techniques,
when appropriate, and other forms of
information technology.
SUPPLEMENTARY INFORMATION:
Evaluating the Safety of Antimicrobial
New Animal Drugs With Regard to
Their Microbiological Effects on
Bacteria of Human Health Concern
Description: The guidance document
discusses an approach for assessing the
safety of antimicrobial new animal
drugs with regard to their
microbiological effects on bacteria of
human health concern. In particular, the
guidance describes methodology that
sponsors of antimicrobial new animal
drug applications for food-producing
animals may use to complete a
qualitative antimicrobial resistance risk
assessment. This risk assessment should
be submitted to FDA for the purposes of
evaluating the safety of the new animal
drug to human health. The guidance
document outlines a process for
integrating relevant information into an
overall estimate of risk and discusses
possible risk management strategies.
E:\FR\FM\06JAN1.SGM
06JAN1
]]>Agencies
[Federal Register Volume 70, Number 4 (Thursday, January 6, 2005)]
[Notices]
[Pages 1252-1253]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-288]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
ACTION: Publication of closed meeting summary of the Advisory Board on
Radiation and Worker Health (ABRWH), National Institute for
Occupational Safety and Health (NIOSH).
-----------------------------------------------------------------------
Committee Purpose: This board is charged with (a) providing advice
to the Secretary, HHS on the development of guidelines under Executive
Order 13179; (b) providing advice to the Secretary, HHS on the
scientific validity and quality of dose reconstruction efforts
performed for this Program; and (c) upon request by the Secretary, HHS,
advise the Secretary on whether there is a class of employees at any
Department of Energy facility who were exposed to radiation but for
whom it is not feasible to estimate their radiation dose, and on
whether there is reasonable likelihood that such radiation doses may
have endangered the health of members of this class.
Background: The Advisory Board on Radiation and Worker Health met
on December 13, 2004, in closed session to discuss Individual Case Dose
Reconstruction Reviews. The discussion involved individual dose
reconstruction case reviews. The individual cases the ABRWH discussed
included personal information of a confidential nature where disclosure
would constitute a clearly unwarranted invasion of personal privacy
and, therefore, could not be disclosed. A Determination to Close the
meeting was approved and published, as required by the Federal Advisory
Committee Act.
Summary of the Meeting: Attendance was as follows:
Board Members:
Paul L. Ziemer, Ph.D., Chair.
Lew Wade, Ph.D., Executive Secretary (Pro Tem).
Antonio Andrade, Ph.D., Member.
Roy L. DeHart, M.D., M.P.H., Member.
[[Page 1253]]
Richard L. Espinosa, Member.
Michael H. Gibson, Member.
Mark A. Griffon, Member.
James M. Melius, M.D., Dr.P.H., Member.
Wanda I. Munn, Member.
Charles L. Owens, Member.
Robert W. Presley, Member.
Genevieve S. Roessler, Ph.D., Member.
NIOSH Staff:
Fred Blosser, Cori Homer, Stu Hinnefeld, Liz Homoki-Titus, Ted
Katz, Rob McGolerick, Jim Neton, and Diane Porter.
DOL Staff:
Shelby Hallmark, Jeff Kotsch, Jeff Nesvet, and Pete Turcic.
GAO Staff:
Mary Nugent.
SC&A Staff:
Hans Behling, Joe Fitzgerald, John Mauro.
Ray S. Green, Court Recorder.
Summary/Minutes
Dr. Ziemer called to order the Advisory Board on Radiation and
Worker Health (ABRWH) in closed session on December 13, 2004 at 1:30
p.m. The purpose of the closed meeting was to discuss the Individual
Case Dose Reconstruction Reviews. This action will allow the ABRWH to
fulfill its statutory duty to advise the Secretary of Health and Human
Services on the scientific validity and quality of dose estimation and
reconstruction efforts being performed for purposes of the compensation
program under EEOICPA.
General topics discussed:
Closed session procedures.
Case reviews presented.
Prepared motion for consideration by the full Board
regarding how to proceed with the 20 cases; the motion was approved by
unanimous vote, then shared and discussed in open session by the Board
on the following day. Dr. Paul Ziemer adjourned the closed session of
the ABRWH meeting at 4:50 p.m. with no further business being conducted
by the ABRWH.
Contact Person for More Information: Larry Elliott, Executive
Secretary, ABRWH, NIOSH, CDC, 4676 Columbia Parkway, Cincinnati, Ohio
45226, telephone 513/533-6825, fax 513/533-6826.
The Director, Management Analysis and Services Office, has been
delegated the authority to sign Federal Register notices pertaining to
announcements of meetings and other committee management activities for
both CDC and the Agency for Toxic Substances and Disease Registry.
Dated: December 30, 2004.
B. Kathy Skipper,
Acting Director, Management Analysis and Services Office, Centers for
Disease Control and Prevention.
[FR Doc. 05-288 Filed 1-5-05; 8:45 am]
BILLING CODE 4163-19-P
